AWTTC informs NHS Wales, the MA holder and any clinical experts and patient groups involved with the assessment process, about the final decision. Ratified recommendations are also disseminated to NHS Wales colleagues through established internal communications channels.
All AWMSG advice for licensed and off-label medicines is published on the AWTTC website. The decision rationale and the assessment report are also made available, as well as the Equality and Health Impact Assessment for each medicine assessed.